Biosimilar and Biosuperior Anti-TNF Antibodies from CHI
Reporter: Aviva Lev-Ari, PhD, RN
Start by reviewing Fundamentals of BioSimilars:
Lev-Ari, A. 7/30/2012 Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers
Lev-Ari, A. 7/29/2012 Biosimilars: Financials 2012 vs. 2008
https://pharmaceuticalintelligence.com/2012/07/30/biosimilars-financials-2012-vs-2008/
Lev-Ari, A. 7/29/2012 Biosimilars: CMC Issues and Regulatory Requirements
Continue by reviewing 2016 Report on BioSimilars:
SOURCE
From: Daniel Miller <danielm@healthtech.com>
Date: Wednesday, August 10, 2016 at 1:20 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Frason
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply